The Society for Reproductive Investigation (SRI) and Bayer are pleased to announce the SRI and Bayer Discovery/Innovation Grants, which will provide seven (7) individuals a one-year grant in the amount of $15,000 each, in 2018-2019. The deadline for the award application is November 15, 2017.
“SRI is excited to partner with Bayer to fulfill our mission of advancing women’s health,” said Sandra T. Davidge, PhD, president of SRI. “Through these grants, Bayer and SRI demonstrate a commitment to research in reproductive medicine.”
The program offers grants to scientists and clinicians dedicated to research in endometriosis (including adenomyosis uteri/endometriosis internal), uterine fibroids (uterine leiomyoma) and Polycystic Ovarian Syndrome (PCOS).
“As part of Bayer’s longstanding commitment to advancing women’s health, supporting scientific and clinical research in key areas of unmet need is a priority,” said Karl Ziegelbauer, PhD, senior vice president and head of therapeutic research groups in drug discovery at Bayer. “We’re delighted to partner with SRI to support researchers working toward potential treatment options that seek to improve the lives of women suffering from gynecological conditions.”
Bayer has a robust product portfolio and research pipeline in women’s health, including family planning and gynecological diseases.
Bayer will provide a total of $105,000 to fund seven grants, to be awarded in March 2018 at the SRI’s 65th Annual Meeting. The Requests for Applications are available through SRI until November 15, 2017. The application review and all grant award decisions are within the sole discretion of SRI. For more information, please contact the SRI Office at email@example.com or (414) 918-9888.
The Focus Areas: Novel treatment options and animal models include:
Complete information and instructions for submitting an application can be found by clicking here.
For more information please contact the SRI Office at firstname.lastname@example.org or 414-918-9888.
Please read the instructions very carefully. Please note that the deadline cannot be extended for any reason.